Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: life extension

Several billionaires, most of them Californians, have been funding firms involved in developing life-extension technologies. What if they succeed? What if billionaires alive today live indefinitely and get ever richer?

February saw the announcement in Silicon Valley by X Prize founder, serial entrepreneur, and all-round gee-whiz future-technology promoter Peter Diamandis that he had cofounded a new company called Celularity.

He did so together with Dr. Bob Hariri, a renowned biomedical entrepreneur known for innovations in harvesting placental stem cells. Hariri had previously founded Celgene Cellular Therapeutics.

Read more

Celularity, a leading U.S. biotechnology company, is seizing on an opportunity to use cells to target diseases. The CEO, Dr. Robert Hariri, says placenta can be used to augment longevity and immunity. https://www.celularity.com

Celularity’s Massively Transformative Purpose (MTP) is to harness the power of the living cell to augment biology, immunity and longevity.

/redirect?q=http%3A%2F%2Fwww.foxbusiness.com%2Ffeatures%2F2018%2F02%2F15%2Fbiotech-breakthrough-placenta-makes-100-years-old-new-60-research-finds.html&v=jkQV3gUua_8&event=video_description&redir_token=QKlLB38bGZR8iE-br1upaZX8KUh8MTUyMDg4MzgwNEAxNTIwNzk3NDA0

Read more

Enzymes play an important role in cognitive function. Enzymes are biological catalysts. They’re responsible for accelerating chemical reactions.

What role do enzymes play in #aging and cognitive function?

According to new research in laboratory mice by UC San Francisco scientists have discovered that loss of an #enzyme that modifies gene activity to promote brain regeneration may be partly responsible for age-related cognitive decline. When age related cognitive decline starts is still debatable, however the effects of age related cognitive decline are well known.

Read more

Some cancer cells express some of the same genes that senescent cells do, so it makes sense that drugs that destroy senescent cells may also destroy cancer cells. This was what the researchers in this new study set out to test.

However, in this experiment, the researchers discovered that the chosen senolytic drugs were not effective at destroying cancer cells with senescence-associated gene expression. While cancer cells and senescent cells do share some common properties, they are also quite different at an epigenetic level.

The researchers did, however, demonstrate that a so-called “suicide gene therapy” that causes both senescent cells and cancer cells to kill themselves worked by targeting senescence-associated p16Ink4a. This approach is similar to that of SENS spin-off company Oisin Biotechnologies, which is using a suicide gene therapy to eliminate senescent cells.

Read more

And what the media and scientists think of it.

Aubrey de Grey, Ph.D., Vice President of New Technology Discovery at AgeX Therapeutics, discusses the “Methuselarity” — the point at which technology enables humans to live to more than 1,000 years of age. Dr. de Grey believes this could happen within the coming decades and posits that some people born today may live to be 1,000 years of age. He further states that people who are 30 years old today have a 50/50 chance to live to be 1,000 years old. Dr. de Grey bases his assumptions on the research into aging that companies like Agex Therapeutics are pursuing. This video is the third in a series from AgeX about the future of aging and its impact on humanity. For more information on the company, please visit www.agexinc.com.

Read more

Two pivotal conferences on the topic of “death” coming up!!

First at the INSERM Liliane Bettencourt School on March 16–18 will be “Death: From Cells to Societies — Aging, Dying, and Beyond” -

Then, April 11–13 at Harvard Medical School, will be “Defining Death: Organ transplantation and the 50-year legacy of the Harvard report on brain death”

http://bioethics.hms.harvard.edu/annual-bioethics-conference-2018

An important inflection point for all!!

On the run up to Undoing Aging 2018, Nicola Bagalà from LEAF did an interview to learn a bit more about our foundation and the story of our involvement in life extension.

As our readers probably already know, from March 15 to March 17 this year, the Undoing Aging 2018 Conference will be held at the Umspannwerk Alexanderplatz in Berlin, Germany. The event is intended to bring together scientists working on repair-based therapies for aging as well as to give life sciences students—and anyone else who may be interested, really—an occasion to deepen their understanding of the current state of rejuvenation research.

Organised by the Forever Healthy Foundation and the SENS Research Foundation, the conference will feature eminent researchers among its many speakers, such as the director of the Wake Forest Institute for Regenerative Medicine, Dr. Anthony Atala; Dr. Kristen Fortney, who is an expert on computational drug discovery and aging biomarkers; Dr. Michael West, co-CEO of BioTime and founder of Geron Corporation; Dr. James Kirkland, a world-class expert on cellular senescence; and Dr. Vera Gorbunova, a pioneer of the comparative biology approach to the study of aging and co-director of the Rochester Aging Research Center. In addition to its scientific, educational, and networking value, UA2018 will no doubt greatly contribute to the popularisation of this area of research and help spread awareness, both about the problem represented by age-related diseases and the great opportunity we have to finally bring aging under comprehensive medical control within a relatively short time frame.

LEAF, naturally, will attend the event to keep you fully up to date, and our readers can expect extensive coverage during and following the event. Meanwhile, to whet your appetite, we caught up with Forever Healthy’s founder and CEO, Michael Greve, to learn a bit more about his foundation and the story of his involvement in life extension.

Read more